OakChart

OptimizeRx Corp

OPRXHealthcare·Health Information Services·USA·Micro·NASD·Nov 11 • 3:31 PM ET

9.11-0.24 (-2.51%)
2026-11-11 21:31 CET
Market cap
176.12 USD m
Revenue, TTM
98.65 USD m
Net income, TTM
4.60 USD m
Free cash flow, TTM
18.61 USD m
EPS diluted, TTM
0.24
P/E
38.75
Compare

Price

OPRX against its 20, 50 and 200-day averages
2050200beatearnings
6.008.0010.0012.001.1M2.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OPRXclose 9.1220-day 9.1350-day 8.43200-day 7.199.1252w low

45.9% under the 52-week high of 16.84 on 11 Nov 2025. 52-week low 4.54 on 23 Jun 2026. Last 15 sessions, 17.8% high to low

Volume 1.19× normal · the line is the 50-bar volume average

Profile

OPRX
52-week range, 37% of the way up
4.5416.84

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Employees133
IPOMay 18, 2005
Beta1.15
ATR, 14d0.53
Rel volume1.19
Short float7.42%
Insider own14.99%
Inst own68.82%

Snapshot

6 groups

Valuation

Index-
Market Cap171.69M
Enterprise Value167.07M
Income4.60M
Sales98.65M
Book/sh6.96
Cash/sh1.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees133
IPOMay 18, 2005

Ratios

P/E38.75
Forward P/E8.73
PEG13.86
P/S1.74
P/B1.31
P/C7.12
P/FCF9.23
EV/EBITDA10.72
EV/Sales1.69
Quick Ratio5.58
Current Ratio5.58
Debt/Eq0.15
LT Debt/Eq0.14
Option/ShortYes / Yes

Earnings

EPS (ttm)0.24
EPS next Y1.04
EPS next Q0.16
EPS this Y-16.57%
EPS next Y19.18%
EPS next 5Y0.63%
EPS past 3/5Y- -
Sales past 3/5Y20.56% 20.37%
EPS Y/Y TTM145.91%
Sales Y/Y TTM-5.82%
EPS Q/Q-146.40%
Sales Q/Q-29.77%
EarningsNov 11 AMC
EPS/Sales Surpr.44.01% 1.47%

Ownership

Insider Own14.99%
Insider Trans0.00%
Inst Own68.82%
Inst Trans-9.28%
ROA2.76%
ROE3.68%
ROIC3.09%
Gross Margin68.88%
Oper. Margin11.45%
Profit Margin4.66%
SMA20-0.20%
SMA508.15%
SMA20026.78%
Trades-

Technical

Shs Outstand18.83M
Shs Float16.01M
Short Float7.42%
Short Ratio6.62
Short Interest1.19M
52W High16.84 -45.87%
52W Low4.54 100.77%
Volatility8.36% 5.77%
ATR (14)0.53
RSI (14)52.67
Beta1.15
Rel Volume1.19
Avg Volume179.33K
Volume197,807

Performance

Perf Week-7.18%
Perf Month8.19%
Perf Quarter3.82%
Perf Half Y85.45%
Perf YTD-25.65%
Perf Year-42.64%
Perf 3Y-0.05%
Perf 5Y-88.96%
Perf 10Y210.03%
Recom1.00
Target Price12.60
Prev Close9.35
Price9.11
Change %-2.51%

Analyst ratings

latest 10 of 12
DateActionAnalystRating changeTargetImplied
Sep 29, 2026ResumedRB. Riley SecuritiesBuy$11+20.7%
Jan 08, 2025DowngradeRRBC Capital MktsOutperform → Sector Perform$7 → $6-34.2%
Dec 20, 2024InitiatedSStephensEqual-Weight$5.50-39.7%
Jul 25, 2024ResumedRB. Riley SecuritiesBuy$18.50+103.0%
Apr 04, 2024InitiatedJJMP SecuritiesMkt Outperform$15+64.6%
Jan 03, 2024InitiatedBBarclaysEqual Weight$15+64.6%
Feb 02, 2023ResumedRB. Riley SecuritiesBuy$30+229.1%
Nov 01, 2022InitiatedSStifelBuy$19+108.4%
Jul 15, 2022InitiatedSSVB LeerinkOutperform$38+316.9%
Oct 18, 2021ResumedRB. Riley SecuritiesBuy$102+1,019.0%

Peers

Mkt cap
TickerCompanyMkt cap
DOCSDoximity Inc5.95B
PHRPhreesia Inc798.85M
DHDefinitive Healthcare Corp187.39M
GDRXGoodRx Holdings Inc1.23B
VEEVVeeva Systems Inc49.62B
HCATHealth Catalyst Inc108.56M
CERTCertara Inc1.79B
IQVIQVIA Holdings Inc45.58B
ZDZiff Davis Inc1.71B
MGNIMagnite Inc4.20B

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Stelmakh EdwardChief Finance & Strat OfficerDec 19 '25Option Exercise0.005,2370128,218Dec 22 10:10 AM
Stelmakh EdwardChief Finance & Strat OfficerDec 19 '25Sale13.511,38818,752126,830Dec 22 10:10 AM
Silvestro Stephen LChief Executive OfficerDec 19 '25Option Exercise0.006,5460195,462Dec 22 10:10 AM
Odence-Ford MarionChief Legal & Admin OfficerDec 19 '25Option Exercise0.003,928094,526Dec 22 10:09 AM
Besch DougChief Product & Tech OfficerDec 19 '25Option Exercise0.001,964071,536Dec 22 10:07 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 95.28B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
EESWisdomTree U.S. SmallCap FundAUM: 684.87M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B

News

latest 14 of 200
  • OptimizeRx Rallied 38% On Margins; Now It Must Show Demand Has Stopped Shrinking (Earnings Whispers) +5.25%
  • OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET (GlobeNewswire)
  • OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel (GlobeNewswire)
  • OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network (Stocktwits)
  • OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath (GlobeNewswire)
  • OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence (GlobeNewswire) +7.13%
  • OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference (GlobeNewswire)
  • OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor (GlobeNewswire)
  • OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ... (GuruFocus.com) +24.72%
  • OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth (GlobeNewswire)
  • OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance (GlobeNewswire)
  • Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside (GuruFocus.com)
  • OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET (GlobeNewswire)
  • OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-11-0.162--21.195
2026Q22026-08-120.1600.111-0.04020.5020.205
2026Q12026-05-120.1400.053-0.02619.8418.746
2025Q42026-03-050.5100.2240.25932.2430.917
2025Q32025-11-060.2000.0370.04026.0723.557
2025Q22025-08-070.2400.0170.08129.2022.267
2025Q12025-05-120.080-0.120-0.11921.9318.697
2024Q42025-03-120.3000.272-0.00432.3230.708
2024Q32024-11-130.1200.059-0.49821.3124.998
2024Q22024-08-080.020-0.064-0.22018.8120.167
2024Q12024-05-14-0.110-0.128-0.38019.6918.136
2023Q42024-04-160.2600.384-0.22828.3727.925
2023Q32023-11-060.0900.025-0.17216.3315.146
2023Q22023-08-14-0.010-0.021-0.24513.8214.807
2023Q12023-05-10-0.090-0.080-0.37413.0012.367
2022Q42023-03-080.2500.241-0.01919.7021.777

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-0.210-0.150-0.21012.1311.52
2018FY0.2600.2000.01921.2120.47
2019FY0.0700.123-0.23524.6024.79
2020FY0.2000.190-0.14943.3142.90
2021FY0.4500.4260.02161.2961.14
2022FY0.3500.349-0.64362.4564.57
2023FY0.2600.374-1.02671.5271.08
2024FY0.3300.309-1.09992.1390.17
2025FY1.0500.7460.270109.43108.11
2026FY-0.876--96.23
2027FY-1.044--106.6
2028FY-1.070--107.74

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2760221.1920.5021.51
2026Q3S2026-10-0160621.1920.5021.51
2026Q3S2026-09-2860621.5520.5023.51
2026Q3S2026-08-1360621.6220.5023.51
2026Q3S2026-08-1260025.4624.0027.73
2026Q3S2026-07-2760025.4624.0027.73
2026Q3S2026-07-2660525.4624.0027.73
2026Q3S2026-06-0960625.4624.0027.73
2026Q3S2026-06-0370725.4724.0027.73
2026Q3S2026-05-1370725.4724.0027.73
2026Q3S2026-05-1270729.5827.7331.00
2026Q3S2026-04-0771630.1328.6031.63
2026Q3S2026-03-0670730.0128.6031.00
2026Q3S2026-01-2770032.0630.8034.10

Estimate history

EPS, annual-0.210.019-0.235-0.1490.021-0.643-1.026-1.0990.270.2352
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.22-0.498-0.004-0.1190.0810.040.259-0.026-0.037
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual12.12721.20624.59843.31361.29362.4571.52292.127109.42998.65
Period201720182019202020212022202320242025TTM
Sales, quarterly18.81221.30932.31721.92829.19526.06732.23919.84420.504
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual9.77312.03914.60115.22317.86117.07418.15818.45318.7618.833
Period201720182019202020212022202320242025MRQ
Shares, quarterly18.32118.32818.45318.49318.55618.59218.7618.76518.833
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue98.65109.4392.1371.5262.4561.2943.3124.6021.21
Cost of Goods Sold Incl. D&A30.7040.1637.0831.0241.2533.2324.4612.7011.84
Gross Profit67.9569.2755.0540.5021.2028.0618.8611.909.37
Selling, General and Administrative Excl. Other56.6657.2156.9953.7233.4927.7020.9914.798.58
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income11.2912.06-1.95-13.22-12.290.36-2.14-2.890.79
Interest Expense4.685.296.161.450.000.000.000.000.00
Unusual Expense0.370.3711.7611.040.000.000.141.430.61
Net Income Before Taxes6.786.95-19.39-25.16-11.440.38-2.21-4.040.23
Income Taxes2.181.820.72-7.600.000.000.00-0.900.00
Consolidated Net Income4.605.13-20.11-17.57-11.440.38-2.21-3.140.23
Net Income From Continuing Operations4.605.13-20.11-17.57-11.440.38-2.21-3.140.23
Net Income4.605.13-20.11-17.57-11.440.38-2.21-3.140.23
EPS (Recurring)0.260.28-0.65-0.57-0.640.02-0.14-0.160.05
EPS (Basic, Before Extraordinaries)0.250.28-1.10-1.03-0.640.02-0.15-0.230.02
EPS (Diluted)0.240.27-1.10-1.03-0.640.02-0.15-0.230.02
EBITDA15.5816.392.38-10.82-10.272.45-0.06-1.611.10
Non-Operating Income (Expense)0.530.550.480.550.850.020.070.290.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.285.509.0610.8415.755.493.171.652.52
Price To Earnings Ratio39.7539.75---3,906.29---
Price To Sales Ratio1.092.130.973.434.7817.9310.675.596.14
Gross Margin68.8863.3059.7556.6233.9545.7843.5448.3644.18
Operating Margin11.4511.02-2.11-18.49-19.680.59-4.93-11.763.71
Net Margin4.664.69-21.83-24.56-18.320.62-5.10-12.781.07
Shares Outstanding18.8318.7618.4518.1617.0717.8615.2214.6012.04
Market Capitalization176.12176.1289.53259.76288.171,103.66470.78145.56131.79

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue20.5019.8432.2426.0729.2021.9332.3221.31
Cost of Goods Sold Incl. D&A5.885.989.229.6311.639.6811.398.96
Gross Profit14.6213.8723.0216.4417.5612.2520.9312.35
Selling, General and Administrative Excl. Other14.7113.4714.0914.3914.3714.3617.3013.43
Research and Development3.273.40------
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.090.408.942.053.19-2.113.63-1.07
Interest Expense1.131.161.241.151.601.301.561.52
Unusual Expense0.000.000.370.000.000.000.007.49
Net Income Before Taxes-1.10-0.647.471.051.71-3.282.21-9.94
Income Taxes-0.39-0.152.450.270.18-1.082.29-0.82
Consolidated Net Income-0.70-0.495.020.781.53-2.20-0.08-9.12
Net Income From Continuing Operations-0.70-0.495.020.781.53-2.20-0.08-9.12
Net Income-0.70-0.495.020.781.53-2.20-0.08-9.12
EPS (Recurring)-0.04-0.030.270.040.08-0.12-0.00-0.21
EPS (Basic, Before Extraordinaries)-0.04-0.030.270.040.08-0.12-0.00-0.50
EPS (Diluted)-0.04-0.030.260.040.08-0.12-0.00-0.50
EBITDA0.981.4610.023.134.26-1.024.730.02
Non-Operating Income (Expense)0.120.120.140.150.130.130.140.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.741.441.551.551.181.232.322.06
Price To Earnings Ratio39.7524.10------
Price To Sales Ratio1.091.102.173.642.451.700.971.60
Gross Margin71.3269.8971.4163.0560.1555.8664.7657.97
Operating Margin-0.432.0027.727.8610.92-9.6411.25-5.04
Net Margin-3.43-2.4915.572.995.25-10.03-0.24-42.82
Shares Outstanding18.8318.7718.7618.5918.5618.4918.4518.33
Market Capitalization176.12117.83228.53380.58249.68160.1389.53141.45

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments23.3613.3813.8574.1484.6810.5218.858.915.12
Short Term Receivables38.5038.2137.2922.1624.8017.897.426.463.43
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.852.383.192.285.634.460.870.590.26
Total Current Assets64.7253.9754.3398.58115.1132.8627.1415.968.81
Net Property, Plant & Equipment0.510.520.720.370.470.590.740.150.17
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets111.67116.39127.7535.7025.3926.8628.688.940.78
Other Assets0.030.300.570.010.010.010.080.010.01
Total Assets176.92171.17183.37134.65140.9960.3356.6425.059.76
Short Term Debt Incl. Current Port. of LT Debt4.452.172.220.090.090.120.120.000.00
Accounts Payable1.642.162.231.550.610.620.490.410.46
Income Tax Payable0.000.32-------
Other Current Liabilities15.1814.0113.436.768.679.295.503.823.09
Total Current Liabilities21.2618.6517.888.409.3710.036.114.233.54
Long Term Debt21.6631.0234.600.140.240.330.450.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities5.714.494.34------
Other Liabilities0.000.000.000.000.000.005.222.370.00
Total Liabilities48.6254.1756.828.549.6110.3511.786.603.54
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity128.29117.00126.55126.11131.3849.9744.8618.466.22
Total Shareholders Equity128.29117.00126.55126.11131.3849.9744.8618.466.22
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity128.29117.00126.55126.11131.3849.9744.8618.466.22
Total Liabilities & Stockholders Equity176.92171.17183.37134.65140.9960.3356.6425.059.76
Book Value Per Share6.846.346.977.397.363.283.071.530.64
Tangible Book Value Per Share0.890.03-0.075.305.931.521.110.790.56
Full-Time Employees133129136949757503724
Price to Book Ratio1.340.782.272.378.449.493.347.157.59
Return on Assets2.95-11.34-11.05-8.300.38-3.77-7.691.30-19.81
Return on Equity4.18-16.51-13.90-8.880.42-4.65-9.931.83-29.99
Return on Invested Capital3.42-13.59-10.90-9.060.29-4.39-6.941.23-33.82
Quick Ratio3.042.893.0411.7412.293.284.443.772.49
Current Ratio3.042.893.0411.7412.293.284.443.772.49

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income4.605.13-20.11-17.57-11.440.38-2.21-3.140.23
Depreciation4.294.334.332.402.022.092.081.280.32
Other Funds (Non Cash)9.458.4420.0023.4716.115.573.512.082.52
Funds from Operations18.3417.904.228.316.698.043.380.223.07
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.341.070.92-15.553.96-7.31-9.69-1.88-2.27
Cash from Operating Activities18.6818.965.14-7.2410.650.73-6.31-1.660.79
Capital Expenditures0.01-0.06-0.45-0.87-0.24-0.49-0.12-1.59-0.09
Net Assets From Acquisitions0.000.000.00-82.950.000.000.00-8.99-5.60
Sale of Fixed Assets and Businesses0.000.000.002.550.000.000.000.00-
Purchase or Sale of Investments0.000.000.0055.93-55.930.000.000.000.00
Purchase of Investments0.000.000.00-162.78-55.930.000.000.000.00
Sale Or Maturity of Investments0.000.000.00218.710.000.000.000.000.00
Other Uses0.000.000.000.00-2.000.000.000.000.00
Other Sources0.130.130.000.000.000.000.000.000.00
Cash from Investing Activities0.140.07-0.45-25.34-58.18-0.49-0.12-10.58-5.69
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.350.350.00-7.80-18.9575.542.4922.188.69
Repurchase of Common Pref Stock0.000.000.00-7.98-20.020.000.000.000.00
Sale of Common Pref Stock0.350.350.000.181.0775.542.4922.188.69
Proceedsfrom Stock Options0.000.000.000.000.0070.670.0021.308.16
Issuance or Reduction of Debt, Net-10.55-8.25-4.2536.020.000.000.000.000.00
Change in Long Term Debt-10.30-8.00-4.0036.020.000.000.000.000.00
Issuance of Long Term Debt24.300.000.0037.730.000.000.000.000.00
Reduction of Long Term Debt-34.60-8.00-4.00-1.710.000.000.000.000.00
Net Financing Active Other Cash Flow-1.12-1.15-0.910.000.00-1.61-4.390.000.00
Other Financing Activities Uses-1.12-1.15-0.910.000.00-1.61-4.390.000.00
Cash from Financing Activities-11.32-9.05-5.1628.22-18.9573.92-1.9022.188.69
Net Change in Cash7.519.98-0.47-4.36-66.4774.16-8.349.943.79
Free Cash Flow18.6118.915.03-7.3310.570.63-6.38-1.750.76
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow5.7712.3217.69-28.261,756.04--171.64
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments24.1020.1723.3619.5216.5916.57
Short Term Receivables27.1232.8638.5033.9734.1632.83
Inventories0.000.000.000.000.000.00
Other Current Assets2.933.142.852.833.342.31
Total Current Assets54.1556.1664.7256.3254.0851.71
Net Property, Plant & Equipment0.570.460.510.600.660.45
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets109.58110.62111.67113.31114.36115.38
Other Assets0.020.020.030.100.160.23
Total Assets164.32167.26176.92170.32169.26167.77
Short Term Debt Incl. Current Port. of LT Debt1.482.184.453.513.513.44
Accounts Payable1.323.071.642.041.983.38
Income Tax Payable--0.000.000.000.00
Other Current Liabilities6.915.2215.1812.9215.5711.53
Total Current Liabilities9.7110.4621.2618.4721.0618.35
Long Term Debt18.0021.5421.6625.1025.4729.36
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities5.525.665.714.493.463.79
Other Liabilities0.000.000.000.000.000.00
Total Liabilities33.2337.6548.6248.0649.9851.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity131.08129.61128.29122.26119.28116.27
Total Shareholders Equity131.08129.61128.29122.26119.28116.27
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity131.08129.61128.29122.26119.28116.27
Total Liabilities & Stockholders Equity164.32167.26176.92170.32169.26167.77
Book Value Per Share6.966.916.846.586.436.29
Tangible Book Value Per Share1.141.010.890.480.270.05
Full-Time Employees--133---
Price to Book Ratio1.340.921.863.192.151.37
Return on Assets2.764.082.950.02-5.77-8.95
Return on Equity3.685.564.180.03-8.21-12.90
Return on Invested Capital-0.47-0.333.350.531.06-1.51
Quick Ratio5.585.373.043.052.572.82
Current Ratio5.585.373.043.052.572.82

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-0.70-0.495.020.781.53-2.20
Depreciation1.061.061.081.081.071.09
Other Funds (Non Cash)2.482.192.652.131.931.73
Funds from Operations2.852.758.753.994.530.63
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.76-3.22-1.41-0.790.033.24
Cash from Operating Activities8.61-0.477.343.204.563.86
Capital Expenditures-0.04-0.020.08-0.01-0.04-0.08
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.130.000.000.00
Cash from Investing Activities-0.04-0.020.21-0.01-0.04-0.08
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.010.340.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.010.340.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-4.61-2.69-2.75-0.50-4.50-0.50
Change in Long Term Debt-4.61-2.69-2.50-0.50-4.50-0.50
Issuance of Long Term Debt24.300.000.000.000.000.00
Reduction of Long Term Debt-28.91-2.69-2.50-0.50-4.50-0.50
Net Financing Active Other Cash Flow-0.05-0.02-0.96-0.10-0.01-0.09
Other Financing Activities Uses-0.05-0.02-0.96-0.10-0.01-0.09
Cash from Financing Activities-4.66-2.71-3.70-0.26-4.50-0.59
Net Change in Cash3.93-3.203.852.930.013.19
Free Cash Flow8.58-0.497.333.194.553.84
Price to Free Cash Flow5.778.0812.5733.2124.2423.60

Revenue breakdown

Life Science Companies2024: 85.47M 2025: 109.21M
Other2024: 6.66M 2025: 215.00K
United States2024: 92.13M 2025: 109.43M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.42%1.2M16.0M182.05K
2026-10-156.74%1.1M16.0M196.93K
2026-09-306.97%1.1M16.0M227.09K
2026-09-156.30%1.0M16.0M296.71K
2026-08-317.26%1.2M16.0M325.68K
2026-08-147.15%1.2M16.1M369.39K
2026-07-318.47%1.4M16.0M422.85K
2026-07-159.10%1.5M16.0M466.01K
2026-06-307.04%1.1M16.0M479.54K
2026-06-1511.54%1.9M16.1M474.07K
2026-05-2910.63%1.7M16.3M530.18K
2026-05-1512.37%2.0M16.3M527.78K
2026-04-3013.20%2.2M16.4M502.30K
2026-04-1513.82%2.2M15.6M477.49K
2026-03-3112.73%2.0M15.6M444.62K
2026-03-1310.19%1.6M15.6M382.84K
2026-02-279.02%1.4M15.5M317.45K
2026-02-1310.79%1.7M15.5M290.73K
2026-01-3010.78%1.7M15.5M278.91K
2026-01-1510.51%1.6M15.5M270.08K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.506.507.800.0011.9350.000.000.984-0.0150.001
call5.004.105.200.005.9490.000.000.870-0.1060.003
call7.501.952.402.352.8252041,0160.738-0.0870.005
call10.000.500.600.601.64524426.000.409-0.0510.006
call12.500.000.250.131.9076.007.000.190-0.0420.004
call15.000.001.400.062.6031.000.000.154-0.0500.003
put2.500.000.050.007.3140.000.00-0.041-0.0530.001
put5.000.000.950.006.0530.000.00-0.134-0.1040.003
put7.500.001.000.403.3375300.00-0.260-0.0870.005
put10.001.051.301.051.3334101.00-0.591-0.0500.006
put12.502.603.700.002.1130.000.00-0.812-0.0410.004
put15.005.006.200.003.0020.000.00-0.846-0.0480.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-21SCHEDULE 13G/ASEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-20S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-14SCHEDULE 13GSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-07SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-22SCHEDULE 13GSEC
2026-06-128-KCurrent report2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-06-058-KCurrent report2026-06-01SEC
2026-06-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120018.75K1
2025-110000

Institutional holders

Manager% owned
Whetstone Capital Advisors, LLC8.04%
ROYCE & ASSOCIATES LP6.98%
VANGUARD CAPITAL MANAGEMENT LLC3.73%
KENNEDY CAPITAL MANAGEMENT LLC3.43%
RICE HALL JAMES & ASSOCIATES, LLC3.38%
BLAIR WILLIAM & CO/IL3.27%
AQR CAPITAL MANAGEMENT LLC3.11%
BlackRock, Inc.2.37%
DIMENSIONAL FUND ADVISORS LP2.35%
Parkman Healthcare Partners LLC1.87%

Funds

Fund% owned
Royce Small-Cap Opportunity Fund2.72%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.63%
Jacob Internet Fund1.83%
U.S. SMALL CAP VALUE PORTFOLIO1.22%
VANGUARD EXTENDED MARKET INDEX FUND1.00%
Invenomic Fund0.89%
Fidelity Small Cap Index Fund0.84%
Clearwater Select Equity Fund0.69%
Fidelity Extended Market Index Fund0.51%
Jacob Discovery Fund0.47%

OakChart. OPRX. Cached 15 minutes.